Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Emergent BioSolutions received a $22.3 million order modification to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War. The order is part of an existing contract to provide the vaccine for military use. According to the company, this supports preparedness against biological threats like anthrax.

Original reporting
Published Nov 4, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EBS
Bullish
medium confidence
Mentioned
$EBS
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EBSBullishLow
01

Why it matters

The contract modification confirms ongoing demand for anthrax vaccine and may bolster the company's revenue outlook, though the amount is modest relative to its total earnings.

02

Market read

A new government contract adds incremental revenue and reinforces the company's defense‑biotech positioning, offering a modest bullish catalyst.

03

What to watch

Potential future extensions or volume increases beyond the $22.3 M could amplify revenue impact if not disclosed.

Relevance 5/10Novelty 6/10Timing: immediate

Background

Emergent BioSolutions is a leading supplier of medical countermeasures for biological threats, with a history of government contracts for vaccines such as BioThrax.

Company-level read

Ticker impact

$EBSBullishMedium confidence
Context

Emergent BioSolutions announced a $22.3 million modification to its IDIQ contract to supply BioThrax anthrax vaccine to the U.S. Department of War.

Expected impact

likely modest upside as investors price in the new contract revenue

Evidence & confidence

A $22 M government contract is material for a mid‑cap biotech but not large enough to drive a sharp move; the news is new and confirms ongoing demand.

Market effects

Supports the broader defense‑biotech sector by confirming continued government spend on counter‑bioterror products.

U.S. defense contractors may see slight positive sentiment.

Limited to investors tracking U.S. government contract pipelines.

Counterpoint

The contract size is too small to offset broader market risks for biotech stocks, so the news may be already priced in.

Key entities

  • Emergent BioSolutions Inc.

    U.S. biotech firm supplying BioThrax vaccine to the Department of War.

  • U.S. Department of War

    The contracting agency for the anthrax vaccine supply.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)